Skip to main content

Table 2 Infrastructure for HBV testing/treatment in Madagascar in 2016

From: Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO’s elimination strategy

  Total number No. of facilities in the capital region (Antananarivo) No. of facilities in other regions Price
Public Private Public Private
1. Screening for HBV
 HBsAg assay ELISA 3 2 1 0 0 $ 10
Point-of-care test 74 11 22 29 12 $ 2–5
2. Clinical staging
 AST & ALT 77 13 23 29 12 $ 2–5
 HBV DNA PCR assay 0 0 0 0 0 N/A
 Fibroscan® 0 0 0 0 0 N/A
 Hepatologist 5 3 0 2 0 N/A
3. Treatment
 HBV treatment Lamivudine 1 0 1 0 0 $ 0.7/dose
Tenofovir 0 0 0 0 0 N/A
  1. Abbreviations: ELISA enzyme-linked immunosorbent assay, N/A not applicable
\